A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Herombopag
Interventions
DRUG

herombopag olamine tablets

The patient received herombopag 5mg/d at the beginning of the day, was orally taken on an empty stomach in the morning, and could eat 2 hours after taking the drug, once a day for 24 weeks. Investigators will adjust the dosage of herombopag once a week according to the platelet count, with a maximum dosage of 7.5 mg per day. Efficacy and safety were evaluated once a week.

Trial Locations (1)

Unknown

RECRUITING

Chinese academy of medical science and blood disease hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER